Immuneering announced encouraging mid-stage clinical trial results for atebimetinib, its oral MEK inhibitor for pancreatic cancer. The combination of atebimetinib with chemotherapy yielded an 86% nine-month survival rate in the first-line treatment setting. These outcomes support plans to initiate a pivotal phase 3 trial within the year, representing a significant step forward in addressing a malignancy notorious for poor prognosis and therapeutic resistance.